A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
A phase 2 trial of vudalimab in ovarian cancer, endometrial cancer, cervical cancer and prostate cancer, run by Xencor, Inc., active and no longer recruiting.
Overview
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies is a phase 2 interventional study registered as NCT05032040 by Xencor, Inc., with 170 participants enrolled, started 2022-07-21 and due to reach its primary completion in 2025-10-15. Interventions recorded: vudalimab.
Similar pages
not linked directly; found by shared links- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Endometrial cancer, Cervical cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialBXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
Shares ICON plc and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Shares ICON plc and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialA Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
- TreatmentLorigerlimab
Shares Endometrial cancer, Cervical cancer, Ovarian cancer and the tag pipeline.